Drug Profile
Anti-cancer/anti-rheumatoid arthritis monoclonal antibody biosimilar - Zydus Cadila
Alternative Names: MAB 1Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in India (Parenteral)
- 28 Feb 2014 Clinical trials in Cancer in India (Parenteral)